Subsequently, ECHDC2 was knocked down or overexpressed in GBM cell lines, and its effects on cell proliferation and migration were determined using CCK-8, EdU, wound-healing, and Transwell migration assays.<h4>Results</h4>Upregulated ECHDC2 expression was significantly correlated with unfavorable clinicopathological features and reduced overall survival (OS) in patients with GBM. Here, ECHDC2 is linked to glioblastoma.